Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States.

ABSTRACT:

Introduction

Patients with fibrosing interstitial lung disease (ILD) experience a decline in lung function with progressive symptoms, poor response to treatment, and reduced quality of life. While supplemental oxygen therapy is commonly prescribed in clinical practice for patients with fibrosing ILD, the long-term outcomes associated with oxygen therapy remain unclear. This study aimed to address this knowledge gap.

Methods

This non-interventional study used the Optum^® Market Clarity database from 01 October 2015 to 30 June 2022. Patients aged ≥ 18 years with newly diagnosed fibrosing ILD (≥ 2 fibrosing ILD diagnoses on different service dates within 365 days) were included. Patients meeting initial selection criteria were assigned to cohorts based on oxygen thera

SUBMITTER: Yang J 

PROVIDER: S-EPMC12619349 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature